Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
- 31 January 2007
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 104 (1), 212-216
- https://doi.org/10.1016/j.ygyno.2006.07.045
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Drug resistance in ovarian cancer: from the laboratory to the clinicPublished by Wolters Kluwer Health ,2006
- Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian StudyJournal of Clinical Oncology, 2005
- Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is There a Correlation with “Biological Aggressiveness” and Survival?Gynecologic Oncology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Splenectomy and Surgical Cytoreduction for Ovarian CancerGynecologic Oncology, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Treatment Results and Prognostic Factors in a Population-Based Study of Epithelial Ovarian CancerGynecologic Oncology, 1993
- Resection of diaphragmatic peritoneum and muscle: Role in cytoreductive surgery for ovarian cancerGynecologic Oncology, 1989
- AnnouncementGynecologic Oncology, 1986